Honeywell plans to spin off its advanced materials division, generating $3.7-$3.9 billion in revenue, into a new public company by 2026. Cerebras Systems is likely to delay its IPO due to a CFIUS review over foreign investment. Tokyo Metro's $2.35 billion IPO is multiple times oversubscribed internationally and will begin trading on October 23, 2024. TenneT explores a spin-off or stake sale of its $21.95 billion German unit.

In a recent Reuters article, IPOX® Research Analyst Dr. Lukas Muehlbauer discussed the strong debut of Upstream Bio (UPB.O) in the IPO market. The Waltham, Massachusetts-based drug developer saw its stock rise 26.5% above the IPO price, giving it a market value of $1.05 billion.

Several high-profile IPOs are set to debut across global markets. AI chipmaker Cerebras Systems plans a major Nasdaq listing, while Brazilian fintech PicPay and digital lender K Bank target significant offerings in 2025. In Europe, payments firm Ebury and sports supplements company Applied Nutrition prepare for London IPOs. Chinese AI firm Horizon Robotics seeks to raise $500 million in Hong Kong, and food delivery giant Talabat is eyeing a blockbuster Dubai listing with a potential valuation up to $15.1 billion.

Major upcoming IPOs include Titan America's expected $500 million raise in early 2025, potentially valuing it over $2 billion, and Spring Nature's anticipated IPO, possibly valuing the company at $10 billion by late 2024. In Asia, Midea Group raised $3.98 billion in Hong Kong's largest IPO in four years, while Enflame Technology aims to raise $280 million, targeting Shanghai's STAR board in late 2024.

Major upcoming IPOs include Titan America's expected $500 million raise in early 2025, potentially valuing it over $2 billion, and Spring Nature's anticipated IPO, possibly valuing the company at $10 billion by late 2024. In Asia, Midea Group raised $3.98 billion in Hong Kong's largest IPO in four years, while Enflame Technology aims to raise $280 million, targeting Shanghai's STAR board in late 2024.

In a recent Reuters article, IPOX® research analyst Lukas Muehlbauer highlighted strong institutional and retail demand for Bicara Therapeutics' IPO, which raised $315 million after upsizing twice. Bicara’s shares surged 46% in its debut, driven by confidence in its lead anti-cancer drug and notable backing from TPG and Biocon.

Several major IPOs are expected, including Titan America’s $500 million U.S. listing, Samsonite’s dual U.S.-Hong Kong offering, and Midea Group’s $3 billion Hong Kong IPO, the largest in the region since 2021. Carlyle’s Acrotec Group could raise $4.7 billion in Zurich. Other notable deals include Delivery Hero’s Talabat listing in Dubai and Advanta Enterprises planning a $500 million IPO in India by 2025.

In Bloomberg, IPOX® CEO Josef Schuster discussed the resurgence of SPACs, noting $2 billion raised in August. He emphasized SPACs as a viable alternative to traditional IPOs for niche sectors, with renewed interest from sponsors. IPOX® tracks these trends as companies explore new public listing avenues.

MBX Biosciences, specializing in GLP-1 drugs, has filed for a Nasdaq IPO. Delivery Hero plans to list its MENA unit, Talabat, in Dubai with a valuation of around $5.5 billion. Tembo E-LV will go public via a $904 million SPAC deal. Duality Biotherapeutics is preparing for a Hong Kong IPO, focusing on its ADC pipeline. NMDC Energy is launching an IPO in Abu Dhabi to raise $877 million.